Many patients develop nutritional deficiencies or require follow-up surgery.
Many patients develop a remarkable compensatory heightening of other, non-linguistic powers and skills, especially the ability to "read" other people.
By precisely tracking how many patients develop surgical infections, for example, and why, Cincinnati Children's has been able to identify ways to reduce that number by more than half — to 42 last year compared with 95 in 2005.
Many patients develop abnormally protruding upper jaws, prominent cheekbones, and marrow expansion in the long bones, ribs, or vertebrae, which fracture easily.
Although local hepatectomy is possible for solitary BCLM, many patients develop recurrent disease [4].
In spite of promising new therapies, many patients develop resistance and progression.
Many patients develop castration resistance (castration-resistant PCa [CRPC]) after approximately 2 3 yr, with a poor prognosis.
Many patients develop distal radioulnar joint (DRUJ) pain and loss of forearm rotation after distal radial fractures.
Despite these advances, many patients develop substantial range of motion limiting adhesions after primary flexor tendon repair.
The first therapeutic anti-CD20 mAb, rituximab, is a murine human chimera to which many patients develop antibodies and/or experience infusion-related reactions.
Even after potentially curative surgery (R0 resections), many patients develop recurrent disease, for which the treatment options are very limited [3].
